Patanjali promised the Supreme Court its cure claims would stop — the ads kept coming

In November 2023 the Indian Medical Association took Patanjali Ayurved — Baba Ramdev's billion-dollar consumer and ayurvedic group with some 47,000 stores — to the Supreme Court over at least 30 misleading ads claiming its products could cure everything from blood pressure and diabetes to obesity and Covid-19. Ramdev and managing director Acharya Balkrishna gave the court a formal undertaking: no more efficacy claims in any media, no more disparaging modern medicine. The very next day, Ramdev issued a press statement saying Patanjali had run trials on more than 10 million people.

The court ran out of patience in February 2024: contempt notices went to the company, Balkrishna, and Ramdev personally, and Patanjali was barred from advertising any product addressing the 54 diseases covered by the Drugs and Magic Remedies Act, 1954. The bench accused the central government of 'sitting with eyes closed' while the country was 'taken for a ride'. When no reply to the contempt notice was filed by March 19, the founders were ordered to appear in person. Two newspaper apologies were rejected as insufficient, and Uttarakhand cancelled licences for 14 Patanjali products.

In August 2024 the court accepted the apology — noting the company had taken steps to rectify its mistake — and closed the contempt proceedings with a warning: comply with all future orders and never repeat the conduct, or the case reopens. The episode turned a 1954 statute most consumers had never heard of into front-page news, and established that a doctors' association could drag India's most aggressive health-claim advertiser into open court.

No fine in the contempt case — but two rejected apologies, an ad ban under the 1954 Act, 14 product licences cancelled, and founders summoned as contemnors.

The undertaking was signed for the courtroom but the brand kept selling in the market: the cure-claim advertising was not a side campaign, it was the company's core growth engine.

The next-day press statement converted a legal promise into immediate proof of breach — the fastest possible route from regulatory dispute to personal contempt liability.

The apologies were framed as public relations, not concessions; judges read the repetition as disdain and escalated instead of closing the file.

Regulators stayed inert while 53 complaints accumulated between 2022 and 2023, so the judiciary took over — and a product-marketing case became a public rebuke of the entire enforcement apparatus.

If your growth engine is a claim the law forbids, signing an undertaking does not fix the engine. Every ad that runs after the promise is not marketing any more — it is evidence.

On August 12, 2024, a bench of Justices Hima Kohli and Ahsanuddin Amanullah closed the contempt case against Patanjali, Ramdev and Balkrishna, accepting their apology while warning it would reopen on any future violation. Uttarakhand's cancellation of 14 product licences remained the one concrete regulatory action of the saga. The IMA's petition kept the Drugs and Magic Remedies Act — dormant for decades — in daily headlines. Patanjali kept its stores and its market, but its most powerful marketing weapon was legally quarantined.